Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev. Inst. Med. Trop. Säo Paulo ; 59: e5, 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-842773

RESUMEN

ABSTRACT Clinical and laboratory parameters including blood and cerebrospinal fluid (CSF) neopterin were investigated in human-T-lymphotropic-virus-type-I associated-myelopathy/tropical-spastic-paraparesis-HAM/TSP and in HTLV-I carriers. HAM/TSP (n = 11, 2 males/9 females, median age = 48 years), recently diagnosed HTLV-I carriers (n = 21, 15 females/6 males, median age = 44 years), healthy individuals (n = 20, 10 males/10 females, median age = 34.6 years) from the Brazilian Amazon (Manaus, Amazonas State) were investigated. Neopterin was measured (IBL ELISA Neopterin, Germany) in serum samples of all the participants, in CSF of 9 HAM/TSP patients as well as in 6 carriers. In HAM/TSP patients, CSF cell counts, protein and glucose were measured, the Osame’s motor-disability-score/OMDS was determined, and brain/spinal cord magnetic-resonance-imaging (MRI) was performed. HAM/TSP patients had normal CSF glucose, leukocyte counts; and normal protein levels predominated. Brain-MRI showed white-matter lesions in 7 out of 11 HAM/TSP patients. OMDS varied from 2-8: 9 were able to walk, 2 were wheel-chair-users. The median serum neopterin concentration in HAM/TSP patients was 6.6 nmol/ L; min. 2.8- max. 12.5 nmol/ L); was lower in carriers (4.3 nmol/L; min. 2.7- max. 7.2 nmol/ L) as well as in healthy participants (4.7 nmol/ L; min. 2.7- max. 8.0 nmol/ L) (p < 0.05). CSF neopterin concentrations in HAM/TSP patients were higher than in serum samples, and higher compared to carriers (p < 0.05). Carriers had similar serum-CSF neopterin concentrations compared to healthy participants. Variable clinical and laboratory profiles were seen in HAM/TSP patients, however our results support the neopterin measurement as a potential biomarker of disease activity.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Virus Linfotrópico T Tipo 1 Humano , Neopterin/sangre , Neopterin/líquido cefalorraquídeo , Paraparesia Espástica Tropical/sangre , Paraparesia Espástica Tropical/líquido cefalorraquídeo , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Brasil , Portador Sano , Estudios de Casos y Controles , Imagen por Resonancia Magnética
2.
Mem. Inst. Oswaldo Cruz ; 110(7): 914-920, Nov. 2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-764594

RESUMEN

Leprosy inflammatory episodes [type 1 (T1R) and type 2 (T2R) reactions] represent the major cause of irreversible nerve damage. Leprosy serology is known to be influenced by the patient’s bacterial index (BI) with higher positivity in multibacillary patients (MB) and specific multidrug therapy (MDT) reduces antibody production. This study evaluated by ELISA antibody responses to leprosy Infectious Disease Research Institute diagnostic-1 (LID-1) fusion protein and phenolic glycolipid I (PGL-I) in 100 paired serum samples of 50 MB patients collected in the presence/absence of reactions and in nonreactional patients before/after MDT. Patients who presented T2R had a median BI of 3+, while MB patients with T1R and nonreactional patients had median BI of 2.5+ (p > 0.05). Anti-LID-1 and anti-PGL-I antibodies declined in patients diagnosed during T1R (p < 0.05). Anti-LID-1 levels waned in MB with T2R at diagnosis and nonreactional MB patients (p < 0.05). Higher anti-LID-1 levels were seen in patients with T2R at diagnosis (vs. patients with T1R at diagnosis, p = 0.008; vs. nonreactional patients, p = 0.020) and in patients with T2R during MDT (vs. nonreactional MB, p = 0.020). In MB patients, high and persistent anti-LID-1 antibody levels might be a useful tool for clinicians to predict which patients are more susceptible to develop leprosy T2R.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/inmunología , Glucolípidos/inmunología , Inmunoglobulina M/sangre , Lepra Multibacilar/diagnóstico , Anticuerpos Antibacterianos/inmunología , Susceptibilidad a Enfermedades , Ensayo de Inmunoadsorción Enzimática , Inmunoglobulina M/inmunología , Mycobacterium leprae/inmunología
3.
Rev. Soc. Bras. Med. Trop ; 37(5): 384-390, set.-out. 2004. tab, graf
Artículo en Portugués | LILACS | ID: lil-365855

RESUMEN

O eritema nodoso hansênico é evento inflamatório agudo no curso crônico da hanseníase. É considerado evento de base imunológica e importante causa de morbidade e incapacidade física. Avaliou-se o perfil clínico, sorológico e histopatológico de 58 pacientes com eritema nodoso hansênico recrutados sequencialmente entre julho-dezembro de 2000, em área urbana hiperendêmica do Brasil Central (Estado de Goiás). A metade dos pacientes apresentava quadro reacional grave, e em 66 por cento dos casos o primeiro episódio reacional ocorreu durante tratamento específico. A maioria dos casos com eritema nodoso hansênico e dos controles apresentaram reatividade para IgM anti-PGL I. Os achados histopatológicos mais freqüentes no eritema nodoso hansênico foram infiltrado neutrofílico, paniculite, vasculite e agressão neural. Dos pacientes com eritema nodoso hansênico, 96 por cento usaram corticosteróide sistêmico no primeiro episódio. Os casos de eritema nodoso hansênico estavam associados à neurite e raramente usaram talidomida como medicação isolada nos serviços de saúde.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Antígenos Bacterianos/sangre , Eritema Nudoso , Glucolípidos/sangre , Inmunoglobulina M/sangre , Lepra Dimorfa , Lepra Lepromatosa , Estudios de Casos y Controles , Corticoesteroides/uso terapéutico , Enfermedades Endémicas , Eritema Nudoso/tratamiento farmacológico , Eritema Nudoso/microbiología , Eritema Nudoso/patología , Lepra Dimorfa/tratamiento farmacológico , Lepra Dimorfa/inmunología , Lepra Dimorfa/patología , Lepra Lepromatosa/tratamiento farmacológico , Lepra Lepromatosa/inmunología , Lepra Lepromatosa/patología , Leprostáticos/uso terapéutico , Prednisona/uso terapéutico , Índice de Severidad de la Enfermedad , Talidomida/uso terapéutico , Población Urbana
4.
Mem. Inst. Oswaldo Cruz ; 99(4): 393-398, Jun. 2004. ilus
Artículo en Inglés | LILACS | ID: lil-363857

RESUMEN

The goal of this study was to investigate the pattern of inflammatory response induced by Lagochilascaris minor in murine experimental model. For this purpose 115 mice were given 1000-3000 L. minor infective eggs "per os" and 51 uninfected mice were considered as controls. Four hours post-inoculation (PI), 3rd stage larvae were seen passing through the mucosa of terminal ends of small intestine. Six hours PI larvae were observed as an embolus inside the portal vein and also migrating through the liver parenchyma. During the first 24 h larvae-containing eggs of L. minor were observed in the lumen of intestinal tract. Two days PI larvae were seen migrating through lung parenchyma associated with an initial neutrophilic perivasculitis. From the 13th day of this experimental study, L. minor larvae were found mainly in skeletal muscles, in the center of granulomas. Concentric fibrosis with mixed inflammatory infiltrate involved the larvae after the 47th day PI, persistently. This experimental murine study with L. minor indicated that the 3rd stage larvae penetrated via ileum-cecal mucosa reaching the liver and probably other tissues through the hematogenic via. Throughout its pathway the larvae induced a granulomatous reaction, with abundant polimorphonuclear cells.


Asunto(s)
Humanos , Animales , Masculino , Femenino , Niño , Adulto , Ratones , Nematodos , Infecciones por Nematodos , Modelos Animales de Enfermedad , Larva , Ratones Endogámicos C57BL , Factores de Tiempo
5.
An. bras. dermatol ; 77(4): 389-407, jul.-ago. 2002. ilus
Artículo en Portugués, Inglés | LILACS | ID: lil-343208

RESUMEN

O eritema nodoso hansênico (ENH) ou reação tipo 2 é síndrome inflamatória aguda que ocorre antes, durante ou após o tratamento da hanseníase, freqüentemente interrompendo o curso crônico da infecção pelo M. Leprae. O ENH é considerado importante causa de morbidade em meio aos pacientes com hanseníase, e, sem pronta assistência médica, pode ocasionar danos neurais, paralisias e deformidades. Atualmente, os episódios de ENH estão entre as principais causas de hospitalização desses pacientes em muitas regiões endêmicas brasileiras. Esse artigo, revisa dados epidemiológicos do ENH em diferentes fontes, apresentando padrão histopatológico e descrição concisa do mecanismo imunológico. Propõe critérios clínicos semi-objetivos para a clssificação clínica da gravidade do ENH, para aplicação no campo. A talidomida é considerada a droga de escolha para o tratamento dessa síndrome, de acordo com o programa oficial de controle da hanseníase. Corticoterapira sistêmica é mandatória para o tratamento da neurite periférica, da irite/iridiciclite e orquite associadas com o ENH. O artigo destaca ainda a lacuna de dados disponíveis sobre os episódios reacionais e o uso indiscriminado de corticosteróide na rotina. Um efetivo sistema de vigilância, incluindo farmacovigilância, é necessária para detectar efeitos adversos dos corticosteróides no novo contexto da eliminação da hanseníase


Asunto(s)
Humanos , Masculino , Femenino , Eritema Nudoso , Lepra
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA